-
Allergan's Chief R&D Officer Talks Avycaz, Assembly Biosciences And 6 'Potential Blockbusters' In The Pipeline
Monday, February 13, 2017 - 4:13pm | 718Early Monday, Allergan plc Ordinary Shares (NYSE: AGN) — one of the world's largest pharmaceutical companies that produces branded and generic drugs, and performs pharmaceutical research and development — announced its recent acquisition of Zeltiq Aesthetics. Benzinga had the privilege...
-
Tobira Therapeutics Up 760% Following Allergan Buyout, Liver Drug A Key Focus
Tuesday, September 20, 2016 - 10:29am | 365Tobira Therapeutics Inc (NASDAQ: TBRA), a clinical-stage bio-pharmaceutical company that focuses on the development of therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, soared higher by more than 760 percent on Tuesday after the company agreed to sell itself to...
-
Actavis' Avycaz Delivers A One-Two Punch To Superbugs
Friday, March 6, 2015 - 3:15pm | 632Historically, the U.S. Food and Drug Administration has not exactly been a “speed demon” when it comes to approving new drugs. Thanks to the Generating Antibiotics Incentives Now (GAIN) Act and forward-thinking companies like Actavis plc (NYSE: ACT) that are taking advantage of that...